AI assistant
MEMPHASYS LIMITED. — Capital/Financing Update 2012
Oct 29, 2012
65314_rns_2012-10-29_4992f996-40b7-4473-89af-d5d1b04bf9f8.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [197 x 25] intentionally omitted <==
==> picture [197 x 25] intentionally omitted <==
==> picture [197 x 25] intentionally omitted <==
==> picture [197 x 24] intentionally omitted <==
FOR IMMEDIATE RELEASE
NuSep Makes a 15% Placement
Sydney, Australia 30[th] October 2012 – The Board of NuSep (ASX:NSP) wishes to advise the market that it has agreed to place 15% of its issued capital at 7¢ per share raising $1,167,090.75. This placement has been taken up by a sophisticated investor based in Singapore.
This placement will be made in three tranches as follows:
| Tranche | Payment Date | Number of Shares |
Dollar Value |
Non-refundable Deposit |
Total Amount |
|---|---|---|---|---|---|
| Tranche One |
30th October 2012 |
6,000,000 | $420,000 | $100,000 | $520,000 |
| Tranche Two |
30thNovember 2012 |
6,000,000 | $420,000 | Nil | $420,000 |
| Tranche Three |
31stDecember 2012 |
4,672,725 | $327,090.75 | Nil | $227,090.75 |
| Total | $1,167,090.75 |
The initial payment has now been received. A non-refundable deposit of $100,000 has also been paid in order to lock in the 7¢ per share price for Tranches Two and Three. This $100,000 nonrefundable deposit will be offset against the payment of Tranche Three when this is received.
An Appendix 3B for the issue of 6,000,000 shares under Tranche One will be lodged shortly. Shares for Tranche Two and Three will be issued only when the respective payments are received in November and December 2012 as detailed above.
*ENDS*
For more information please contact:
Contact: Swapna Keskar Company Secretary +61 2 8415 7300 [email protected]
About NuSep
NuSep (ASX: NSP) is a publicly listed life sciences company that sells products into the global BioSeparations market. NuSep recently acquired BioInquire which developed the ProteoIQ software enabling NuSep to offer a total Proteomics solution from Fraction to Function . The company has offices in both Sydney Australia and Atlanta, USA.
Contact Details Telephone +61 2 8415 7300 Facsimile +61 2 8415 7399
Email [email protected] Web www.nusep.com ABN 33 120 047 556
NuSep Holdings Ltd 324 Burns Bay Rd Lane Cove NSW 2066
Postal Address P.O. Box 823 Lane Cove NSW 1595
– 2 –
With a 30 year heritage in biological separations, NuSep has forged a world class reputation for its innovative yet simple biological separation techniques including the world’s first IVF sperm separation device. In short NuSep has redefined the BioSeparations market through innovation and simplification.
NuSep’s world renowned research team has developed an extensive portfolio of patented products. In all, NuSep currently manufactures, distributes and sells 55 products to customers in the USA, Europe, Asia and Australia.
NuSep Products:
==> picture [12 x 17] intentionally omitted <==
- Gels – NuSep manufactures and sells precast gels including the innovative nUView Gels, which can be visualised 2 minutes after use.
==> picture [12 x 17] intentionally omitted <==
- Separation Instruments – NuSep has developed two unique biological separation instruments. The ProteomeSep was released in 2009 and can separate biological samples into 8 fractions for use in the proteomic market. The SpermSep separates sperm for fertility treatments such as IVF.
==> picture [12 x 17] intentionally omitted <==
- Proteomics Software – NuSep offers the unique ProteoIQ software for the analysis of complex mass spec samples. This software is also designed to identify bio markers.
==> picture [12 x 17] intentionally omitted <==
- Biological Products – NuSep supplies research grade biological products manufactured using its unique separation technologies. These products include human IgG and Albumin .
For more information about NuSep please visit the company’s website www.NuSep.com
About PrIME Biologics Pte Ltd
PrIME Biologics is a Singapore based biotech company that has developed a disposable therapeutic plasma manufacturing process based on NuSep’s PrIME Technology. NuSep has a 90% shareholding in PrIME Biologics. PrIME Biologics process is based on the Pr eparative I solation by M embrane E lectrophoresis (PrIME) technology developed by NuSep. PrIME provides disposable modular processing that is ‘electronically’ driven membrane fractionation.
The PrIME process increases product yields to over 90% relative to the existing process 50% while increasing product safety. The PrIME has been shown to remove virus, bacteria, endotoxins and prions which cause ‘Mad Cow Disease’. Further, PrIME Biologics process can produce multiple plasma products in hours compared to days, which is required by the current manufacturers.
The initial application for the PrIME process will be the Currently Unprocessable Plasma which represents approximately 50% of all the plasma collected in many Asian countries.